BioSpace News Archive

Denver-based health insurer will expand beyond Colorado starting in 2020

Engitix Ltd and Morphic Therapeutic announce that they have entered into a research collaboration to identify ECM-related drug targets in fibrostenotic inflammatory bowel disease, an intestinal fibrosis complication that affects approximately 30 per cent of Crohn’s Disease patients.

ValGenesis, Inc., a market leader in Enterprise Validation Lifecycle Management Solutions (VLMS), today announced that an Agency of the U.S. Federal Government has chosen ValGenesis’s cloud-based, 100% paperless Validation Lifecycle Management System to digitalize their validation lifecycle process.

VistaGen’s PH94B is the first drug candidate to be granted U.S. FDA Fast Track designation for treatment of social anxiety disorder

A-Medicare Vision is to Remake Healthcare in the United States through a competitive high-tech services portal and broad public-private sector interface.

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that it has completed the development process and submitted a Letter to the Design History File and updated the device listing with the U.S. Food and Drug Administration (FDA) for the PXP®-1000 System.

Researchers at Columbia University Discover Link Between Opioid Overdose and Treatment with Buprenorphine.

The NCCN Oncology Research Program will oversee academic/community projects that explore how different health systems can work together to enhance treatment quality for advanced breast cancer patients.

It will commence the full U.S. commercial launch of TACTOSET, its surgically delivered therapy for bone repair procedures, at the Orthopaedic Summit 2019: Evolving Techniques, which will take place December 11-14, 2019 at the Bellagio Hotel in Las Vegas, NV.

The presentation will include new findings from human T-cells demonstrating that GPR174 inhibition results in downregulation of checkpoint and tumor promoting factors.